Skip to content

Time-Effect of Montelukast Protection

Time-Effect of Montelukast on Protection Against Exercise-Induced Bronchoconstriction

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00935415
Acronym
TEMPE
Enrollment
69
Registered
2009-07-09
Start date
2007-01-31
Completion date
2008-08-31
Last updated
2009-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Exercise-Induced Asthma

Keywords

asthma, exercise-induced bronchoconstriction, montelukast, clinical protection, children, time effect

Brief summary

The aim of this study is to verify MNT time of onset of protection against EIB in asthmatic children by evaluating different time intervals between dosing and challenge, after a single-dose and after three days of once a day MNT administration.

Detailed description

Within few days after a baseline exercise challenge, children was randomized to a double blind, placebo-controlled, three day doses, crossover study design. In practice each eligible patient was randomized by a computer-generated schedule to receive in sequence double-blind treatments with placebo or MNT (5 mg). Patients in sequence 1 received MNT, then crossed over to matching placebo; vice versa the case was for patients in sequence 2. Placebo and active treatments were separated by a 7-10 day wash-out period. Each child was assigned to one out of seven groups in order to perform the exercise challenge at different time intervals from drug administration which occurred always at 8.00 A.M. On day one the challenge was performed in the different groups 1, 2, 3, 4, 5, 6, and 8 hours after drug administration, respectively. Then treatment was continued as a single day dose for three consecutive days and a third challenge was then performed at the same time of the day.

Interventions

DRUGMontelukast

Montelukast 5 mg

DRUGPlacebo

capsules of matching placebo

Sponsors

Universita di Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

* children with exercise-induced asthma

Exclusion criteria

* viral infections * montelukast treatment

Design outcomes

Primary

MeasureTime frame
maximal percentage fall in FEV1 after exercise test from the baseline valueat the first and at the third day of single day drug administration

Secondary

MeasureTime frame
clinical protectionat the first and at the third day of single day drug administration

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026